Biogen also markets the multiple sclerosis drugs Avonex and Tysabri. Shares of Biogen Idec Inc. ended regular trading up $5.46, or 1.6
Multiple Sclerosis (MS) (FUSION). Biogen logo. Biogen. Status and phase. Enrolling. Phase 2. Conditions. Relapsing Forms of Multiple Sclerosis.
Biogen (formerly Biogen Idec) for the oral treatment of multiple. Biogen terminates a phase III in Multiple sclerosis (In
F.D.A. Approves a Biogen Drug for Treating Multiple Sclerosis Biogen Inc. said yesterday that it had received approval from the Food and Drug Administration
Due to concerns about the benefits and risks of Zinbryta, Biogen and Abbvie voluntarily withdrew the multiple sclerosis drug from the global
Dimethyl Fumarate in Biogen's Multiple-Sclerosis Drug Tecfidera Qualifies as New Active Substance.
The agreement involves Biogen's drugs Tecfidera and Avonex, both used to treat patients with relapsing forms of multiple sclerosis. Read the
Vial and box for Biogen Idec's multiple sclerosis drug Tysabri. Credit: Biogen Idec. Diagnostic testing will help Biogen Idec's Tysabri
Multiple sclerosis drugs continue to make up the biggest chunk of Biogen's total revenue, but Fampyra is the smallest contributor from this
Comments
A-fucking-mazing.